文献速递免疫规划传染病防控与疫情报告

儿童与青少年无佐剂亚病毒体单价灭活H3N2v流感疫苗的安全性与免疫原性

Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.
PubMed 文献 · Vaccine · 2019-07-30

这项多中心II期开放标签研究评估了无佐剂亚病毒体单价灭活H3N2v疫苗在儿童中的安全性和免疫原性,儿童间隔21天接种两剂。疫苗耐受性良好,6-35月龄儿童无论7.5mcg或15mcg剂量免疫应答均较低,9-17岁儿童一剂后应答良好,且既往流感疫苗接种和年龄较大与更高免疫应答相关。

要点

  • H3N2v疫苗在儿童中耐受性良好,常见局部反应为短暂轻中度压痛、疼痛和红斑。
  • 6-35月龄儿童两剂后HAI和中和抗体应答均较低,9-17岁儿童一剂后应答良好。
  • 既往流感疫苗接种和年龄较大与更高的H3N2v疫苗免疫应答相关。

核心结论

  • H3N2v疫苗在儿童和青少年中安全且具有免疫原性。
  • 观察到针对H3N2v和季节性H3N2病毒的免疫原性随年龄增加,提示既往感染和/或免疫接种的致敏作用。

研究设计与样本

  • 多中心II期开放标签研究,评估间隔21天接种两剂研究性无佐剂亚病毒体单价灭活H3N2v疫苗的安全性和免疫原性。
  • 6-35月龄儿童接受7.5mcg或15mcg血凝素(HA)/剂,3-17岁儿童接受15mcg HA/剂,肌肉注射。

主要发现

  • 疫苗耐受性良好,观察到短暂轻中度注射部位压痛、疼痛和红斑。
  • 6-35月龄儿童最常见报告的系统性反应为易激惹,9-17岁儿童为头痛和疲劳。
  • 6-35月龄儿童无论接受7.5mcg还是15mcg/剂,两剂后HAI和中和抗体应答均低于年长儿童。
  • 9岁以下儿童需要两剂疫苗才能显示应答,而9-17岁儿童一剂后应答良好。
  • 9-17岁儿童还产生了针对近期季节性H3N2流感病毒的交叉反应抗体。

临床怎么用

  • 9-17岁儿童接种一剂H3N2v疫苗后即可产生良好免疫应答。
  • 9岁以下儿童需接种两剂H3N2v疫苗以显示免疫应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In response to the emergence of influenza viruses with pandemic potential, we evaluated a swine-origin influenza A/H3N2 variant (H3N2v) vaccine in children. STUDY DESIGN: This multicenter phase II open-label study assessed the safety and immunogenicity of two doses, 21 days apart, of investigational unadjuvanted subvirion monovalent inactivated H3N2v vaccine administered via intramuscular injection. Children 6-35 months of age received 7.5mcg or 15mcg of hemagglutinin (HA)/dose; children 3-17 years of age received 15mcg HA/dose. Safety and reactogenicity were assessed by measuring the occurrence of solicited injection site and systemic reactions in the 7 days after each vaccination; adverse events were assessed for 42 days and serious adverse events for 7 months after the first vaccination. Immunogenicity was evaluated by measuring hemagglutination inhibition (HAI) and neutralizing (Neut) antibodies to H3N2v prior to and 21 days after each vaccination. Cross-reactivity against seasonal H3N2 strains was evaluated. RESULTS: The H3N2v vaccine was well tolerated. Transient mild to moderate injection site tenderness, pain and erythema was observed, with the most commonly reported systemic reactogenicity being irritability in children 6-35 months, and headache and fatigue in children 9-17 years old. Children 6-35 months old, whether they received 7.5mcg or 15mcg/dose, had low HAI and Neut antibody responses after two doses compared to older children. Children under 9 years of age required two doses of vaccine to demonstrate a response, while 9-17 year olds responded well after one dose. Previous influenza vaccination and older age were associated with higher immune responses to H3N2v vaccine. Children 9-17 years of age also developed cross-reactive antibodies against recent seasonal H3N2 influenza viruses. CONCLUSION: The H3N2v vaccine was safe and immunogenic in children and adolescents. Age-related increases in immunogenicity against H3N2v and seasonal H3N2 viruses were observed, suggesting prior priming via infection and/or immunization. Clinical trial registry: The trial is registered with clinicaltrial.gov: NCT02100436.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Munoz FM, Anderson EJ, Bernstein DI, et al. Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents. Vaccine. 2019. PMID: 31375440. doi:10.1016/j.vaccine.2019.07.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。